Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Authors not listed

Merck Sharp & Dohme LLC · 2003

Abstract

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2003). A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease. <em>Merck Sharp & Dohme LLC</em>. https://clinicaltrials.gov/study/NCT00074529
Vancouver
Anonymous. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease. Merck Sharp & Dohme LLC. 2003.
BibTeX
@misc{anon2003ARando, title = {A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease}, author = {Anonymous}, journal = {Merck Sharp & Dohme LLC}, year = {2003}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings